Imricor Medical Systems (ASX:IMR) said the Na Homolce Hospital in Prague, Czech Republic, will be the third site to join its VISABL-ventricular tachycardia clinical trial, with local ethics committee approval, according to a Wednesday Australian bourse filing.
The trial is evaluating real-time magnetic resonance imaging-guided ventricular ablation.
The company's shares were up nearly 2% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments